ArticleWiener medizinische Wochenschrift (1946)2014
[Tools for optimizing pharmacotherapy for geriatric patients with multimorbidity at the end of life: helpful oder just raising awareness?].
Article in Wiener medizinische Wochenschrift (1946), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Polypharmacy in palliative care-COPD and multimorbidity : A case report.Wiener medizinische Wochenschrift (1946) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacotherapy for end-of-life patients with multimorbidity is a major challenge. Estimating prognosis can be much more difficult when compared to patients suffering from cancer alone.Nevertheless, it is crucial in order to prescribe in the context of the following determining factors: disease, co-morbidities, functional status, life expectancy and therapy goals.Since such patients are prone to adverse drug reactions, inappropriate prescriptions should be avoided, since evidence concerning the benefits or risks for various drugs used is as yet inadequate.Several tools can be of help to improve pharmacotherapy for this vulnerable group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.